SARS-CoV-2 vaccine prophylaxis and mortality among US veterans in 2021.

Chemistry - November 4, 2021 - First Release - DOI: 10.1126 / science.abm0620

Commentary

Vaccines (n= 780,225) covered 2.7% of the US population at the Veterans Health Administration, and from February to October 2021, VE-I dropped from 87.9% to 48.1%, with the largest drop in Janssen vaccine, VE-I was 13.1%.

Breakthrough infections increased the risk of death, but the vaccine continued to prevent death in those infected during the Delta Surge.

From July to October 2021, VE-D at age 65 was 73.0% in Janssen, 81.5% in Moderna, and 84.3% in Pfizer-BioNTech; VE-D at age 65 and older was 52.2% in Janssen, 75.5% in Moderna, and 70.1% in Pfizer-BioNTech. BioNTech was 70.1%.

The findings support continued efforts to increase vaccination, additional immunization campaigns, and multiple additional layers of protection against infection.